UMIN ID: UMIN000002165
Registered date:10/08/2009
Cetuximab biomarker study
Basic Information
| Recruitment status | Complete: follow-up complete |
|---|---|
| Health condition(s) or Problem(s) studied | Recurrent or metastatic colorectal cancer |
| Date of first enrollment | 2009/10/01 |
| Target sample size | 30 |
| Countries of recruitment | Japan |
| Study type | Interventional |
| Intervention(s) | Cetuximab and Irinotecan |
Outcome(s)
| Primary Outcome | correlatopn between biomarkers and efficacy and side effects of cetuximab |
|---|---|
| Secondary Outcome |
Key inclusion & exclusion criteria
| Age minimum | 20years-old |
|---|---|
| Age maximum | Not applicable |
| Gender | Male and Female |
| Include criteria | |
| Exclude criteria | 1.active synchronous malignancy 2.pregnancy 3.severe psychological disease 4.systemic steroid administration 5.HBV carrier 6.uncontrolled diabetes 7.severe fluid collection 8.bowel obstruction 9.cardiovasucular disease within 3months 10.severe comorbidity 11.active infection |
Related Information
| Primary Sponsor | Kobe University Hospital |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | Kobe University Hospital |
| Secondary ID(s) |
Contact
| public contact | |
| Name | Naomi Kiyota |
| Address | 7-5-1 Kusunokicho, chu-oku, Kobe, Hyogo, Japan Japan |
| Telephone | |
| Affiliation | Kobe University Hospital Medical Oncology |
| scientific contact | |
| Name | Hironobu Minami |
| Address | 7-5-1 Kusunokicho, chu-oku, Kobe, Hyogo, Japan Japan |
| Telephone | |
| Affiliation | Kobe University Hospital Medical Oncology |